← Back to Search

Behavioral Intervention

AQ HIV Medication Adherence app-delivered intervention for Sexually Transmitted Diseases (AQ2 Trial)

N/A
Waitlist Available
Led By Kate Muessig, PhD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

AQ2 Trial Summary

This study is evaluating whether a smart phone application can help improve medication adherence for individuals with HIV.

Eligible Conditions
  • Sexually Transmitted Diseases
  • HIV (Human Immunodeficiency Virus)
  • HIV/AIDS
  • Medication Adherence
  • Sexual Activity

AQ2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intervention Acceptability: Mean Intervention Acceptability CSQ-8 Score
Intervention Acceptability: Mean Intervention Acceptability Score
Intervention Feasibility: Average Proportion of Days of Any App Use
+1 more
Secondary outcome measures
Mean Percent ART Medication Adherence Over Time
Mean Percent of Past 30-Day ART Medication Adherence
Number of Participants With Viral Suppression
+1 more

AQ2 Trial Design

4Treatment groups
Experimental Treatment
Group I: AQ+NSC followed by AQExperimental Treatment2 Interventions
At 3 months, those who were initially randomized to AQ+NSC who meet protocol defined definition for intervention responsiveness, may get re-randomized to AQ alone to complete months 4 - 6 of the trial.
Group II: AQ followed by AQ+NSCExperimental Treatment2 Interventions
At 3 months, those who were initially randomized to AQ who meet protocol defined definition for intervention non-responsiveness, are reassigned to AQ+NSC to complete months 4 - 6 of the trial.
Group III: AQ HIV Medication Adherence app-delivered intervention + NSCExperimental Treatment1 Intervention
AQ+NSC: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). NSC sessions are scheduled approximately every other week (frequency) and last approximately 30 minutes per session (dose). The participant may or may not stay on AQ+NSC throughout the study.
Group IV: AQ HIV Medication Adherence app-delivered interventionExperimental Treatment1 Intervention
AQ: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). The participant may or may not stay solely on AQ throughout the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AllyQuest HIV Medication Adherence app-delivered intervention + NSC
2020
N/A
~80
AllyQuest HIV Medication Adherence app-delivered intervention
2020
N/A
~80

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamOTHER
1,590 Previous Clinical Trials
2,281,411 Total Patients Enrolled
9 Trials studying Sexually Transmitted Diseases
5,853 Patients Enrolled for Sexually Transmitted Diseases
Wayne State UniversityOTHER
309 Previous Clinical Trials
109,204 Total Patients Enrolled
1 Trials studying Sexually Transmitted Diseases
400 Patients Enrolled for Sexually Transmitted Diseases
University of North Carolina, Chapel HillLead Sponsor
1,508 Previous Clinical Trials
4,190,971 Total Patients Enrolled
12 Trials studying Sexually Transmitted Diseases
25,234 Patients Enrolled for Sexually Transmitted Diseases

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
AllyQuest Adherence App Intervention for HIV-positive Men Who Have Sex With Men and Transgender Women: Pilot Trial
2020. "AllyQuest Adherence App Intervention for HIV-positive Men Who Have Sex With Men and Transgender Women: Pilot Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03916484.
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top